551 results found

The EPO's Enlarged Board of Appeal has recently made a key ruling on the issue of priority entitlement in decision G1/22 and G2/22.

In the UK, marking patented products as patented is not compulsory. However, there are several benefits to marking products as patented and both guidance from the UK Intellectual Property Office, and UK law...

Patent protection for the use of a known drug in a new method of medical treatment can be achieved at the European Patent Office via a second medical use claim in the format [known drug] for use...

Proteins are a class of macromolecules which carry out a wide range of functions. For example, proteins are essential for photosynthesis, producing energy from food, contracting muscle fibres and DNA replication,...

Food systems are responsible for a third of anthropogenic greenhouse gas emissions, and already half of the world's habitable land is devoted to agriculture.

Universities drive innovation across medicine, AI, materials, and clean tech, but academic researchers face a critical challenge: the need to publish conflicts with patent protection requirements for confidentiality. Understanding how to navigate publication deadlines, filing strategies, and IP development can determine whether groundbreaking research becomes a valuable commercial asset or loses protection entirely.

The European Patent Office (EPO) uses the term "disclaimer" to refer to a negative feature in a claim of a patent application. Negative features are those which exclude certain subject-matter from the scope of protection.

In order to place a new medicinal product on the market in Europe, it is necessary first to obtain a marketing authorisation.

It was developed after the filing date of the basic patent by a licensee which obtained a patent for it, on the basis of which it was granted its own SPC.

The Patent Box makes the existence of a patent more attractive, whatever the breadth of the patent's claim, so long as it covers the product (or process or service).

The European Patent Office's Board of Appeal has referred critical questions to the Enlarged Board of Appeal concerning how patent claims should be interpreted when assessing added subject matter. The referral, pending as G1/26, seeks to clarify whether features from descriptions and drawings can be imported into claim interpretation, and which claim interpretations must be disclosed in the original application to avoid added matter objections.

The UK High Court has rejected a challenge to Novartis's supplementary protection certificate for sacubitril and valsartan, addressing a fundamental question about how the "product" protected by an SPC should be defined. The decision clarifies whether a specific co-crystal formulation or the broader combination of active ingredients constitutes the relevant product under the SPC Regulation.

Over recent years, antibodies have become increasingly important as therapeutic drugs and large numbers of patent applications are filed in this area (>1000 granted by the European Patent Office (EPO) in 2019).

It has now been over two years since launch of the UPC. A key question for users was what the court's approach to assessment of validity would be in practice. In this briefing, we review the approach the UPC has taken...

Inventors are often unaware of the potential variety of IP rights they could obtain to protect their technology, particularly design rights and how they can complement patents.

Crowdfunding can be a great way of raising funds. However, if you fund your business in this way you need to consider carefully how to protect your valuable intellectual property (IP).

In UPC_CoA_789/2025 and UPC_CoA_813/2025, 6 March 2026, Dyson v Dreame, the Court of Appeal has partially stayed proceedings and referred four questions to the CJEU.